Trial Profile

Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Pharmacodynamics

Most Recent Events

28 May 2024 Status changed from recruiting to completed.
21 Mar 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
21 Sep 2020 Planned number of patients changed from 15 to 30.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com